These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16393860)

  • 1. Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Giuliano C; Fiore F; Di Marco A; Padron Velazquez J; Bishop A; Bonelli F; Gonzalez-Paz O; Marcucci I; Harper S; Narjes F; Pacini B; Monteagudo E; Migliaccio G; Rowley M; Laufer R
    Xenobiotica; 2005; 35(10-11):1035-54. PubMed ID: 16393860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species.
    Kalgutkar AS; Choo E; Taylor TJ; Marfat A
    Xenobiotica; 2004 Aug; 34(8):755-70. PubMed ID: 15690763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of an irreversible HCV NS5B polymerase inhibitor.
    Zeng Q; Nair AG; Rosenblum SB; Huang HC; Lesburg CA; Jiang Y; Selyutin O; Chan TY; Bennett F; Chen KX; Venkatraman S; Sannigrahi M; Velazquez F; Duca JS; Gavalas S; Huang Y; Pu H; Wang L; Pinto P; Vibulbhan B; Agrawal S; Ferrari E; Jiang CK; Li C; Hesk D; Gesell J; Sorota S; Shih NY; Njoroge FG; Kozlowski JA
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6585-7. PubMed ID: 24252545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA).
    Rioux N; Smith S; Korpal M; O'Shea M; Prajapati S; Zheng GZ; Warmuth M; Smith PG
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):151-160. PubMed ID: 30386887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
    Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
    Mosure KW; Knipe JO; Browning M; Arora V; Shu YZ; Phillip T; Mcphee F; Scola P; Balakrishnan A; Soars MG; Santone K; Sinz M
    J Pharm Sci; 2015 Sep; 104(9):2813-23. PubMed ID: 25631585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.
    Duan J; Yong CL; Garneau M; Amad M; Bolger G; De Marte J; Montpetit H; Otis F; Jutras M; Rhéaume M; White PW; Llinàs-Brunet M; Bethell RC; Cordingley MG
    Xenobiotica; 2012 Feb; 42(2):164-72. PubMed ID: 21988548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.
    Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP
    Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
    Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
    Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease.
    Monteagudo E; Fonsi M; Chu X; Bleasby K; Evers R; Pucci V; Orsale MV; Cianetti S; Ferrara M; Harper S; Laufer R; Rowley M; Summa V
    Xenobiotica; 2010 Dec; 40(12):826-39. PubMed ID: 20925584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor.
    Wong H; Chen JZ; Chou B; Halladay JS; Kenny JR; La H; Marsters JC; Plise E; Rudewicz PJ; Robarge K; Shin Y; Wong S; Zhang C; Khojasteh SC
    Xenobiotica; 2009 Nov; 39(11):850-61. PubMed ID: 19845436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor.
    Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.
    Obermeier M; Yao M; Khanna A; Koplowitz B; Zhu M; Li W; Komoroski B; Kasichayanula S; Discenza L; Washburn W; Meng W; Ellsworth BA; Whaley JM; Humphreys WG
    Drug Metab Dispos; 2010 Mar; 38(3):405-14. PubMed ID: 19996149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
    Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
    Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of a novel and potent alpha(v)beta3 antagonist in animals, and extrapolation to man.
    Prueksaritanont T; Fernandez-Metzler C; Meng Y; Barrish A; Halczenko W; Rodan SB; Hutchinson JH; Duggan ME; Lin JH
    Xenobiotica; 2004 Jan; 34(1):103-15. PubMed ID: 14742139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
    Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
    Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.